Kezar stalls solid tumour trial to focus on autoimmune disease candidate
Kezar plans to focus all efforts on zetomipzomib, which is being evaluated in two Phase II trials for lupus and autoimmune hepatitis.
Kezar plans to focus all efforts on zetomipzomib, which is being evaluated in two Phase II trials for lupus and autoimmune hepatitis.
What's Your Reaction?
